Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02570711 · ClinicalTrials.gov registry record · Phase 2
Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer
A Phase 2 study, sponsored by Acerta Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT02570711: Clinical Trial Phase 2 study, sponsored by Acerta Pharma.
NCT02570711 is a Phase 2 study that was terminated before completion, run by Acerta Pharma. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02570711, a Phase 2 study, was terminated before completion, sponsored by Acerta Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of ACP-196 and nab paclitaxel/gemcitabine in subjects with previously untreated metastatic pancreatic cancer using standard response criteria
Primary Outcome
The overall response rate (ORR) of ACP-196 plus nab-paclitaxel/gemcitabine compared with nab-paclitaxel/gemcitabine in patients with previously untreated metastatic pancreatic cancer
Interventions
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG ACP-196
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2015-10-13 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
Why NCT02570711 stopped before completion
NCT02570711 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT02570711 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02570711 about?
NCT02570711 is a clinical study titled "Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer". To evaluate the safety and efficacy of ACP-196 and nab paclitaxel/gemcitabine in subjects with previously untreated metastatic pancreatic cancer using standard response criteria
What is the current status of trial NCT02570711?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2015-10-13. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02570711?
The interventions under investigation include: Gemcitabine (DRUG), Nab-paclitaxel (DRUG), ACP-196 (DRUG).
Who is sponsoring clinical trial NCT02570711?
This trial is sponsored by Acerta Pharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02570711's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI